LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer, but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
Clinical data | |
---|---|
Drug class | Progestin; Progestogen |
References
edit- ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.